All Oncology News

The FDA has granted a priority review designation to rociletinib for patients with EGFR T790M-mutant metastatic non–small cell lung cancer following prior administration of an EGFR TKI.

The FDA has granted a priority review designation to eribulin mesylate as a treatment for patients with soft tissue sarcoma following an anthracycline and at least one other regimen.

Overall survival was improved by more than 25 months when lyso-thermosensitive liposomal doxorubicin was administered with optimized (≥45 minutes dwell time) radiofrequency ablation in patients with hepatocellular carcinoma.

Brett Miles, MD, DDS, discusses the potential of ADXS11-001 in HPV-associated head and neck cancer and other emerging therapies and treatment strategies.

Five years from now multiple myeloma will have a therapeutic backbone consisting entirely of combinations of novel agents.

The FDA has granted a priority review designation to a supplemental biologics license application for nivolumab plus ipilimumab in previously untreated patients with advanced melanoma.

Immunotherapy expert Jeffrey Weber, MD, PhD, will join NYU Langone Medical Center's Laura and Isaac Perlmutter Cancer Center as its deputy director and co-director of its melanoma program.

Bart Barlogie, MD, world-renowned myeloma expert who introduced the first curative therapy, a multi-drug regimen known as Total therapy 3, for multiple myeloma joins the faculty of Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai.

The heterogeneity of mantle cell lymphoma will require new combination strategies to improve outcomes.

The attempt by Turing Pharmaceuticals to boost the price of the anti-parasitic pyrimethamine (Daraprim) 5500% is now under reconsideration, owing to a firestorm of public and institutional protest, but it doesn't solve the problem of no limits on what manufacturers can charge and the lack of drug pricing transparency.

Lack of improvement in failure-free survival for patients with follicular lymphoma has fueled interest in new treatment strategies that might offer promise of better outcomes.

Immunotherapy pioneer James P. Allison, PhD, has been named the 2015 recipient of the Lasker-DeBakey Clinical Medical Research Award by the Albert and Mary Lasker Foundation.

Limited clinical evaluation suggests a potentially major role for immune checkpoint inhibition in the treatment of lymphomas, but early success has also raised many questions.

Patients with untreated or relapsed/refractory chronic lymphocytic leukemia achieved durable responses with single-agent ibrutinib (Imbruvica).

Eighteen new research grants, totaling more than $19 million, have been awarded by the FDA for product development in rare diseases such as HPV-related head and neck cancer and recurrent glioblastoma.

The FDA approved the oral nucleoside TAS-102 (Lonsurf) for the treatment of patients with advanced colorectal cancer, based on results from the phase III RECOURSE trial.

Joe O'Sullivan, MD, discusses how radium-223 dichloride (Xofigo), given with concomitant medication, may improve overall survival in patients with metastatic castration-resistant prostate cancer with bone metastases.

Hope Rugo, MD, discusses how to balance the benefits and risks of neratinib, as well as unanswered questions regarding ExteNET, in patients with HER2-positive breast cancer.

The FDA has granted a priority review designation to ofatumumab as a maintenance therapy for patients with relapsed chronic lymphocytic leukemia following a response to second- or third-line therapy.

Renal cell carcinoma with sarcomatoid differentiation, a histology that is often resistant to targeted therapies and interleukin-2 immunotherapy (IL-2), may respond to anti–PD-1/PD-L1 therapies.

Dennis J. Slamon, MD, PhD, discusses the impact of the ADAPT and BOLERO trials and how the increased focus on neoadjuvant therapy with trastuzumab and T-DM1 could transform the treatment of HER2-positive breast cancer.

The FDA has granted a priority review designation to carfilzomib in combination with dexamethasone for patients with relapsed multiple myeloma following prior treatment with at least one therapy.

Molecular profiling of every patient with acute myelogenous leukemia may hold the key to better treatment in the future.

Fitness, age, and disease risk status form the basis for decision-making about first-line therapy for chronic lymphocytic leukemia.

Tom Herzog, MD, discusses the vaccine ADXS11-001 (axalimogene filolisbac) in patients with persistent or recurrent metastatic cervical cancer.

Nivolumab (Opdivo) demonstrated clinical activity and safety in patients with platinum-resistant ovarian cancer.

The USPSTF has issued a draft guideline recommending the use of low-dose aspirin for the prevention of colorectal cancer and cardiovascular disease in adults aged 50 to 59 years.

The American Board of Internal Medicine says it is working to incorporate a set of changes to its physician Certification and Maintenance of Certification requirements that physicians have complained are out of step with the realities of their work.

Trabectedin demonstrated superior disease control compared with dacarbazine in heavily pretreated patients with advanced soft tissue sarcoma.

Titrating dose levels of axitinib (Inlyta) improved response rates and extended overall survival by 12.3 months in patients with metastatic renal cell carcinoma.